Viridian Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022, compared with FY2021. This is an annual report, not a standalone Q4 report; quarterly results are not clearly provided in the filing text.
Business context
Viridian is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead focus is thyroid eye disease (TED), where it is developing IGF-1R antibody candidates VRDN-001, VRDN-002 and VRDN-003. It also has three preclinical programs for undisclosed indications.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $1.8 million | $3.0 million |
| Research and development expense | $100.9 million | $56.9 million |
| General and administrative expense | $35.2 million | $25.8 million |
| Net loss | $129.9 million | $79.4 million |
| Net loss per share, basic and diluted | $4.05 | $6.66 |
| Cash used in operating activities | $93.8 million | $54.6 million |
| Cash used in investing activities | $115.1 million | $74.3 million |
| Cash provided by financing activities | $322.2 million | $125.3 million |
Revenue came from the Zenas BioPharma collaboration, including a $1.0 million development milestone recognized in 2022. The company reported no product-sales revenue. Product margins are therefore not applicable; the filing does not provide a meaningful product-margin measure.
At year-end, cash and cash equivalents were $155.6 million and short-term investments were $269.0 million, totaling approximately $424.6 million. Total assets were $435.1 million, total liabilities $40.0 million, and stockholders’ equity $395.1 million. Accumulated deficit was $488.2 million.
Operating cash use increased by $39.3 million year over year, while net loss increased by $50.5 million. Management said available resources were expected to fund planned operations into the second half of 2025; it also expects to need additional capital. No operating margin is meaningful given the absence of product sales and ongoing development spending.
Material changes and financing
- R&D expense rose $44.0 million, primarily from clinical and preclinical activity, increased personnel costs, licensing and option fees, and manufacturing-related costs. G&A expense rose $9.4 million, mainly reflecting higher personnel and professional costs.
- Other income, net increased to $4.4 million from $0.3 million, largely due to $4.9 million of interest income, partly offset by $0.5 million of interest expense.
- Viridian raised approximately $311.0 million gross in its 2022 public offering and approximately $24.2 million net through its September 2022 at-the-market program. These financings were major sources of 2022 cash and increased the share count.
- The Hercules facility provides access to up to $75.0 million in four tranches, subject to availability conditions and milestones. Viridian drew $5.0 million; the year-end carrying value was $4.6 million. The loan bears floating interest capped at 8.95%, is secured by substantially all borrower assets except intellectual property, and matures October 1, 2026.
Outlook, milestones and risks
- VRDN-001’s Phase 3 THRIVE trial for active TED began enrollment in December 2022; management expected topline results in mid-2024. Chronic TED Phase 1/2 data were expected in Q2 2023, followed by a planned Phase 3 THRIVE-2 trial.
- Viridian planned further subcutaneous development of VRDN-001, VRDN-002 and VRDN-003, expected to select a lead program by year-end 2023, and planned a pivotal Phase 3 trial in mid-2024. These are forward-looking plans, not reported outcomes.
- Management reported positive early VRDN-001 results in 21 active TED patients, including a 71% proptosis-responder rate, a 67% overall-responder rate and no reported serious adverse events in the cited follow-up. These small early-stage results do not establish pivotal efficacy or long-term safety.
- VRDN-002’s Phase 1 healthy-volunteer study reported a half-life of up to 43 days and a favorable, well-tolerated safety profile. Further patient-trial evidence remained pending.
- Key risks include clinical failure or delays, safety findings, financing needs and dilution, reliance on third-party manufacturers and CROs, and competition. The company relied on a single multi-site CDMO and had no redundant supply arrangement. Drug pricing, reimbursement, regulation, intellectual-property protection and macroeconomic conditions also pose risks.
- The FDA had suspended further review of Viridian’s amended VRDN-001 orphan-drug designation application pending additional information; approval was not assured. The company also disclosed related-party arrangements with Zenas BioPharma and Paragon.
- The company reported no material legal proceedings. Its independent auditor issued an unqualified opinion on the financial statements; management stated disclosure controls and internal control over financial reporting were effective at year-end. The auditor identified outsourced clinical-trial and preclinical accruals as a critical audit matter; the related accrued balance was $12.6 million.
Important facts for investors to verify
- Whether actual clinical enrollment, readouts and regulatory steps met the stated timelines, and how complete trial results compare with the early VRDN-001 data.
- Cash burn, investment balances and the assumptions behind the projected runway into the second half of 2025; assess the likelihood, timing and terms of additional financing.
- Remaining availability and conditions on Hercules loan tranches, interest costs, covenants, collateral and repayment obligations.
- Potential dilution from additional ATM sales, equity awards, warrants and conversion of preferred shares.
- Manufacturing capacity and contingency plans if the current CDMO cannot supply trials, as well as the size and timing of licensing milestones, royalties and related-party payments.
- Whether orphan designation is granted and whether future trial data support efficacy, safety, dosing convenience and commercial differentiation against competitors.